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Summary The goal of the study was to identify any normal genes that may become inactivated in malignant
cells, with associated modifications or loss of gene products. Consequently, attempts were made to identify
such products by generating monoclonal antibodies using an immune tolerisation-immunisation procedure.
Using such a technique, a plasma membrane-associated glycoprotein with an apparent molecular weight of
92 kDa was identified. The glycoprotein was termed luminal epithelial antigen (LEA.92). The pattern of
expression of LEA.92 was demonstrated by an indirect immunostaining technique. Using an in vitro model
system representing various stages of breast oncogenesis, LEA.92 was detected on normal or immortalised
mammary epithelial cell (MEC) lines which were dependent on epidermal growth factor (EGF) and anchorage
formation for growth and non-tumorigenic in nude mice. In contrast, LEA.92 was undetectable on
oncogenically transformed or established lines of mammary carcinoma cell lines which were independent of
EGF or anchorage formation for growth and were highly tumorigenic. The results appear to suggest a
correlation between the down-regulation of LEA.92 and the development of tumorigenicity in malignant MEC
lines. Furthermore, the patterns of expression of LEA.92 on breast cells in tissue mirrored those of breast
epithelial cells in cell cultures. LEA.92 was detected on the surface of normal but not malignant epithelial cells,
which included breast, cervix, colon, lung, pancreas and stomach. LEA.92 appeared to be distinct from
receptor for epidermal growth factor, antigens associated with milk fat globule membrane and the family of
epithelium-specific keratins.
The hypopthesis that inactivation of tumour-suppressor
genes plays an important role in the development of human
malignancies has recently received considerable attention
(Knudson, 1985; Stanbridge, 1985, 1987, 1990; Hansen &
Cavenee, 1987; Klein, 1987; Friend et al., 1988; Harris, 1988;
Weinberg, 1989, 1991). To date, various such suppressor
genes, namely retinoblastoma (RB1), Wilms' tumour (WT1),
neurofibrosarcoma (NFl), APC, MCC, p53 and DCC genes,
have been reported and their role in the suppression of
tumour growth documented (Friend et al., 1986, 1988; Lee et
al., 1987; Stanbridge, 1987, 1990; Yuen-Kai et al., 1987;
Lubbert et al., 1988; Baker et al., 1989; Eliyahu et al., 1989;
Takahasi et al., 1989; Vogelstein et al., 1989; Weinberg, 1989,
1991). In view of the success in defining such tumour-
suppressor genes in the above organs, it seems logical to
explore the possible presence of genes with similar functions
in human breast cancer. Evidence for the loss of inactivation
of oncosuppressor gene(s) in breast carcinomas comes from
independent reports that describe allelic losses on several
chromosomes, including lq, Ip, lI p, 13q and 17p and 17q, in
malignant cells from breast (Ali et al., 1987; Lundberg et al.,
1987; Mackay et al., 1988; Chen et al., 1989; Genuardi et al.,
1989). Although relatively gross chromosomal defects have
been observed (Pathak, 1992), the precise genes involved
have not been determined and their specific gene products
have not been identified. Therefore, the purpose of the study
was to identify any normal breast cell products, encoded by
genes that may become inactivated in the malignant counter-
part, with associated loss of the products.
In order to achieve the above-stated goal, the procedure of
tolerisation/immunisation (Imam et al., 1990a) was modified
to favour the production of antibody to any antigens present
preferentially in normal mammary epithelial cells as com-
pared with malignant breast cells. Immune tolerance to mam-
mary epithelial cell lines (MCF.7 and MDA.MB.231 com-
bined) was induced in neonatal mice (within 24 h of birth)
prior to subsequent immunisation with an extract of normal
breast tissue.
This paper reports the identification, generated by the
immune tolerisation/immunisation protocol, of a plasma
membrane-associated glycoprotein with an apparent
molecular weight of 92 kDa (LEA.92) coexpressed on normal
but not malignant epithelial cells in mammary and extra-
mammary tissues and cell lines of normal mammary
epithelium.
Materials and methods
Cell lines
The established human cell lines employed in this study were
obtained from the American Type Culture Collection, Rock-
ville, MD, USA (Table I). These cell lines were cultured in
DMEM supplemented with 100 units ml-' penicillin,
10 gml-' insulin and 10% (v/v) fetal calf serum. In addition
to using the above cell lines, a model system that consists of
a normal human mammary epithelial cell (HMEC) line,
designated 184 (Hammond et al., 1984; Stampfer, 1985),
immortalised MEC lines (designated 184A1 and 184B5)
established from 184 cells by exposure to benzo-[a]pyrene
(Stampfer & Bartley, 1985; Walen & Stampfer, 1989) and a
transformed cell line (designated 184AINI-T-D10) obtained
from 184A1 by exposure to oncogenes (Clark et al., 1988),
reflecting various steps of neoplastic tranformation, was
analysed for the expression of LEA.92. In addition to the
above model, another model system that consists of a non-
tumorigenic immortalised MEC line (HuMI) and its trans-
formed variant of the MuMI-TTul line, which is tumorigenic
in nude mice, was also employed in this study (Ceyhan et al.,
1990).
Preparation ofimmunotolerogen and immunogen
The established lines of human mammary epithelial cells
(MCF.7 and MDA.MB.231) were cultured and washed with
phosphate-buffered saline (PBS) as described previously
(Imam et al., 1985). The washed cells (107cells ml-') were
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lysed with 0.05 M Tris-HCl buffer, pH 7.5, containing 0.15 M
sodium chloride, 1 mM phenylmethylsulphonyl fluoride,
0.5 mM chloromethyl-L-(2-phenyl-1-p-toluenesulphonamide)
ethyl ketone and 0.5% (v/v) Nonidet P-40 (NP-40)
(solubilisation buffer) on ice for 15min. The lysates were
centrifuged at 35,000g and 4°C for 30 min. The supernatants
containing NP-40-solubilised materials from the two cell lines
were pooled (50%, v/v) and used for immune tolerisation,
enzyme-linked immunosorbent assay (ELISA) or immuno-
precipitation.
The normal breast tissues were obtained from two young
women undergoing reduction mammoplasty with no evidence
of abnormality. The tissue samples were pooled and minced,
washed with cold PBS, suspended in solubilisation buffer
without NP-40 (10 g, w/v) and homogenised on ice. The
homogenate was centrifuged at 500g and 4°C for 15 min.
The supernatant was removed and was successively centri-
fuged at 35,000g and 4°C for 30 min and at 100,000g for
1 h. The pellet was recovered and solubilised in the
solubilisation buffer, centrifuged at 100,000g and 4°C for
1 h. The supernatant containing NP-40-solubilised materials
was utilised for immunisation, ELISA and immunoprecipita-
tion.
Generation ofmonoclonal antibodies by a modified
immunisation procedure
Our previous approach to generate antibody against an
antigen present on one cell type (A) but absent from another
(B), against a background of numerous strong antigens com-
mon to both cell types (AB), has been the use of a procedure
that consists of tolerisation of mice with cells of type B,
followed by immunisation with cells of type A (Imam et al.,
1990a). Achievement of tolerance was evaluated by immuno-
histochemical methods, testing sera from mice against the
tolerogen (MCF.7 and MBA.MD.231 combined). Tolerised
mice, showing absence of serum antibodies against the
tolerogen, were subsequently immunised with extracts of
breast tissue containing normal breast cells (immunogen).
Evidence of antibody production was sought by contrasting
positive reactivity for normal MEC with absence of reactivity
for their malignant counterparts by immunohistochemical
methods. The spleen cells from a mouse showing evidence of
serum antibody with these characteristics, and strong reac-
tivity, was subsequently used for hybridisation and produc-
tion of monoclonal antibodies (Imam et al., 1990a,b). The
initial screening of hybridoma supernatants was performed
using freshly frozen tissue sections containing normal or
malignant MEC using an immunohistological staining
method described previously (Imam et al:, 1990a,b). Super-
natants containing antibodies with no reactivity against many
cell types in tissue sections were rejected. A small number of
wells with hybrids secreted antibody that showed strong reac-
tivity with the normal cells, but lacked reactivity against
mammary carcinoma cells in tissue sections. These hybrids
were repeatedly subcloned, until one clone, producing con-
sistently high levels of monoclonal antibody with the above
properties, was selected for detailed study. This antibody was
termed anti-luminal epithelial antigen, LEA.92, to indicate its
reactivity and an apparent molecular weight of the target
antigen. Anti-LEA.92 antibody was purified and also labelled
with biotin as described previously (Imam et al., 1985). Dou-
ble immunodiffusion studies with goat antibodies to a sub-
class of mouse immunoglobulin revealed that anti-LEA.92
antibody is an IgGI immunoglobulin with a kappa light
chain.
Preparation andstaining oftissue sections and cell lines
An indirect unlabelled primary antibody method was used
for the localisation of antigen with the specific antibody-
utilising cell lines and tissue sections as described previously
(Imam et al., 1990a,b). The specificity and pattern of reac-
tivity of anti-LEA.92 antibody were identical in frozen and
formalin-fixed tissue sections, leading to a preference for the
latter, based upon superior morphology and availability of a
large number of tissue specimens. For each experiment,
negative controls were performed to ensure the specificity of
the reaction: these included the use of specific antibody fol-
lowing absorption with the immunogen, non-immune mouse
serum or an irrelevant antibody of the same immunoglobulin
class in lieu of the specific antibody. The visual estimates of
intensities were scored as follows: -, absence; 1 +, weak;
2 +, moderate; and 3 +, intense.
Comparison ofLEA.92 with other known antigens ofepithelial
cells
Competitive immunocytochemically steric interference assays
were performed, using immunocytological techniques (Imam
et al., 1985, 1990b), in order to compare and contrast the
epitope recognised by anti-LEA.92 antibody with those of
epithelial membrane antigen (EMA) (Heyderman et al.,
1979), milk fat globule membrane glycoprotein (MFGM-
gp7O) (Imam et al., 1981, 1984), MFGM-gpl55 (Imam et al.,
1982, 1986), human milk fat globule 1 (HMFG-1) (Arklie et
al., 1981), HMFG-2 (Burchell et al., 1984) and a member of
the keratin family, pan-keratin (Schlegel et al., 1980). The
acetone-fixed cytopreparations of 184 or 184A1 and 184B5
HME cells were incubated first with the unlabelled test
antibodies that included the above antibodies, followed by
incubation with biotinylated antibody to LEA.92. The
remainder of the staining procedure was as described
previously (Imam et al., 1990a,b). Any change in the intensity
of staining with reference to control preparation was
recorded.
Metabolic labelling ofcells andpreparation ofcell tysate
Non-tumorigenic normal (184), non-tumorigenic immor-
talised (184A1, 184B5) or tumorigenic malignant (184A1N4-
T-D1O, MCF.7, MDA-MB-231, MDA-MB-468 or ZR.75)
(MEC) lines were grown as monolayer cultures in 75 mm2
tissue culture flasks and intrinsically labelled when cultures
were still subconfluent. The cells were labelled for 24-48 h
with 2 mCi of either [3H]leucine or [3H]galactosamine
(110 Ci mmol 1) per flask of leucine- or galactosamine-free
DMEM respectively. Following incubation, the cells were
washed three times and lysed with 0.05 MTris-HCl buffer,
pH 7.5, containing 0.15 M sodium chloride, 0.5% (v/v), 0.5%
NP-40 (w/v) sodium deoxycholate, 1 mM phenylmethylsul-
phonyl fluoride and 0.5 mM chloromethyl-L-(2-phenyl-1-p-
toluenesulphosamide) ethyl ketone on ice for 15 min. The
lysates were centrifuged at 40,000g and 4°C for Omin. The
supernatants containing detergent-solubilised materials were
subsequently used for immunoprecipitation.
Sodium dodecyl sulphate-polyacrylamide gel electrophoretic
analysis ofimmunoprecipitants
The radiolabelled cell lysates (approximately 400 ng of pro-
tein containing 5 x I07 c.p.m.) were mixed with 100 ILI of
either anti-LEA.92 antibody (0.1 mgml-') or anti-LEA.92
antibody preabsorbed with the immunogen, non-immune
mouse serum or an irrelevant monoclonal antibody of the
same immunoglobulin class, as described previously (Imam et
al., 1990a,b). The latter antibody served as a negative cont-
rol.
The materials immunoprecipitated with anti-LEA.92 anti-
body were subsequently analysed under chemically non-
reducing (in the absence of 2-mercaptoethanol) or reducing
conditions by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). The solubilised materials were
subjected to electrophoresis in 7.5% polyacrylamide slab gels
in the presence of SDS by the method of Laemmli (1970) and
subjected to fluorography (Imam et al., 1985).A MAMMARY EPITHELIAL CELL-SURFACE GLYCOPROTEIN 441
Results
Immunocytological localisation ofLEA.92 in cell lines
In order to test the in vitro specific expression of LEA.92,
several human breast cell lines were used in an indirect
immunocytochemical staining method. In addition to using
the widely used lines of malignant mammary epithelial cells,
a model system that consists of normal (184), the immor-
talised (184A1, 184B5 or HuMI) and the oncogenically trans-
formed (184AIN1-T-DIO, HuMI-TTul) human mammary
epithelial cell lines was analysed for the expression of
LEA.92.
Non-tumorigenic normal (184) or immortalised (184A1,
184B5, HuMI) MEC lines showed a strong expression of
LEA.92 of their plasma membrane. A representative reac-
tivity with the 184A1 line is shown in Figure 1. The preab-
sorbed anti-LEA.92 antibody, non-immune mouse serum or
an irrelevant monoclonal antibody of the same immuno-
globulin class failed to react with the target cells. In contrast,
the oncogenically transformed tumorigenic MEC lines
(184AIN4-T-DIO or HuMl-TTul) failed to exhibit a detec-
table expression of LEA.92 (Table I). In addition, established
tumour cell lines derived from carcinomas of breast (Table I),
cervix, colon, liver, lung, pancreas, kidney, stomach and
thyroid or melanoma and haematopoietic cell lines (result not
shown) also failed to exhibit a detectable amount of LEA.92
expression.
Specificity ofexpression of LEA.92 on the non-tumorigenic
MEC lines was compared with other known epithelial
antigens, which included human milk fat globule membrane
antigens (e.g. epithelial membrane antigen, EMA; human
milk fat globule membrane glycoproteins, MFGM-gp7O;
MFGM-gpl55; human milk fat globule 1, HMFG-1;
HMFG-2; epithelium-specific pan-keratin; and receptor for
epidermal growth factor, EGF). The immunoblocking assays
showed that the antigenic binding site for anti-LEA.92
antibody was not blocked by other antibodies, suggesting
that the epitope recognised by the antibody is distinct. The
antigen recognised by anti-LEA.92 is also different with
respect to its molecular weight, as shown in Figure 2. Fur-
thermore, in contrast to anti-LEA.92 antibody, antibodies to
the above antigens reacted with all the cell lines included in
Table I.
Localisation ofantigen in tissue sections with anti-LEA.92
antibody
In breast tissues from normal individuals, LEA.92 was exp-
ressed predominantly on the apical plasma membrane of
luminal epithelial cells lining the ducts (Figure 3a). As in
normal breast, benign breast diseases, such as fibroadenoma
or hyperplasia, exhibited the expression of LEA.92. In con-
trast, invasive mammary carcinoma cells of both infiltrating
ductal and infiltrating lobular types failed to exhibit a detec-
table amount of LEA.92 (Figure 3b and Table II). In extra-
mammary tissue, a characteristically similar pattern of ex-
pression of LEA.92 was also observed in various normal
glandular epithelial cells. which included cervix, colon, lung,
pancreas and stomach. As in breast, the expression of
LEA.92 was detectable on normal cells of the above organs,
whereas corresponding malignant epithelial cells in tissue
were consistently negative (Table II). Again, as in the cell
line, antibodies to other known epithelial antigens failed to
discriminate normal from malignant mammary or extramam-
mary epithelial cells in the above tissues.
Characterisation ofthe antigen recognised by anti-LEA.92
antibody
Antigen specifically recognised by anti-LEA.92 antibody was
analysed by immunoprecipitation, SDS-PAGE and fluoro-
graphy. Sources of [3H]galactosamine- or [3H]leucine-labelled
antigen preparations included NP-40 extracts of the estab-
lished (MCF.7 and MDA.MB.231), the oncogenically trans-
formed (184AIN4-T-DIO or HuMI-TTul), the immortalised
(184A1, 184B5, HuMl) and the normal (184) mammary
epithelial cell lines. Fluorigraphic analysis of the
immunoprecipitate obtained by incubation of [3H]galactos-
amine or [3H]leucine-labelled lysates from the normal (184)
or immortalised (184A1 or 184B5) MEC lines with anti-
LEA.92 antibody on SDS-PAGE under reducing conditions
showed a component with an apparent molecular weight of
92 kDa (Figure 2, lane B). The results clearly suggest that
LEA.92 is glycosylated. The apparent molecular weight of
the antigen from these different sources as recognised by the
antibody was identical (results not shown). The antibody
showed no detectable immunoprecipitable component from
the lysate of MCF.7, MDA.MB.231, 184AIN4-T-DIO or
HuMI-TTul, complementing the results obtained in the
immunocytological staining of these cell lines with the
antibody as shown in Table I. Chemical reduction with 2-
mercaptoethanol of immunoprecipitants had no effect on the
migration of the antigen (results not shown). Furthermore,
the preabsorbed anti-LEA.92 antibody, non-immune mouse
Figure 1 Reactivity of anti-LEA.92 antibody to immortalised
mammary epithelial cell line (184A1). The cytopreparations of the
cell line (184A1) were fixed with cold acetone and incubated with
anti-LEA.92 antibody. The antibody shows strong reactivity
predominantly with the cell surface. Following the immunostain-
ing, the cells were counterstained with Mayer's haematoxylin
(original magnification x 200).
Table I Reactivity of anti-LEA.92 antibody with human mammary
epithelial cells by an indirect immunocytological staining methoda
Cell line Reactivity with antibody to LEA.92
Non-tumorigenic in nude mice
184 ++
184A1 + +
184B5 + +
HuMI + +
Tumorigenic in nude mice
184AIN4-T-D1O -
HuMI-TTul -
MCF.7 -
ZR.75.1 -
ZR.75.30 -
MDA.MB.157
MDA.MB.231 -
MDA.MB.468 -
HS 578 T -
HS 746 T -
HS 766 T -
BT-20 -
BT-483 -
BT-549 -
SK-BR-2111 -
SK-BR-3 -
aSamples were scored for intensity on a scale from- to + +:
absence of staining; +, weak staining; + +, intense staining.442 S.A. IMAM et al.
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Figure 2 Sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis analysis of component immunoprecipitated by anti-
LEA.92 antibody. Component immunoprecipitated by the
antibody and [3H]galactosamine-labelled lysate of the non-
tumorigenic immortalised (184AI) mammary epithelial cell line,
lane B. The radiolabelled lysate of 184A1 was also subjected to
immunoprecipitation with the antibody preabsorbed with the
immunogen as shown in lane C. Molecular weight standards are
shown in lane A.
Table II Immunohistological localisation of LEA.92 in formalin-
fixed and paraffin-embedded normal or neoplastic mammary and
extramammary tissue sections
No. of No. of
specimens specimens Intensity of
Histology studied stained staining
Breast, normal 10 10 2 + to 3 +
Breast, benign
Hyperplasia 15 15 1 + to 3 +
Fibroadenoma 15 12 1 + to 3 +
Breast, adenocarcinomas
Infiltrating lobular 30 0 -
invasive
Infiltrating ductal 50 0 -
invasive
Medullary invasive 10 0 -
Mucoid invasive 10 0 -
Metastatic to regional 10 0 -
lymph node
Cervix
Normal 4 4 2 + to 3 +
Adenocarcinoma 4 0
Colon
Normal 4 4 2 + to 3 +
Adenocarcinoma 4 0
Lung
Normal 4 4 1 + to 2 +
Adenocarcinoma 4 4
Pancreas
Normal 4 4 2 + tp 3 +
Adenocarcinoma 2 0
Stomach
Normal 4 4 2 + to 3 +
Adenocarcinoma 4 0 -
Cutaneous melanoma 4 0 -
Spleen, normal 4 0 -
Lymph node, normal 4 0 -
Non-Hodgkin's lymphomas 4 0 -
Hodgkin's disease 4 0 -
Sections were scored for intensity on a scale from - to 3 +; -,
absence of staining; 1 +, weak staining; 2 +, moderate staining; 3 +,
intense staining.
Figure 3 Binding pattern of anti-LEA.92 antibody to mammary
epithelial cells in formalin-fixed and paraffin-embedded tissue
sections by an indirect immunohistological staining method. The
sections were counterstained with Mayer's haematoxylin. The
stromal components were consistently negative. a, Lactating duct.
The antibody exhibited a homogeneous and predcminant reac-
tivity with apical plasma membrane of the lactating mammary
epithelial cells (original magnification x 200). b, Normal (unin-
volved) and infiltrating ductal carcinoma of breast. The unin-
volved duct at the upper left side (short arrow) showed strong
reactivity of predominantly apical plasma membrane with the
antibody, whereas the surrounding malignant cells are completely
unreactive (original magnification x 150).
serum or an irrelevant monoclonal antibody of the same
immunoglobulin class was non-reactive with the previously
positive lysates of [3H]galactosamine- or [3H]leucine-labelled
MEC lines (Figure 2, lane C).
Discussion
In order to reduce the probability of obtaining antibodies to
common immunodominant antigens present on normal mam-
mary epithelial cells and their malignant counterparts, a
method of immune tolerisation/immunisation was used to
generate monoclonal antibodies. The method in principle
favours production, and an enhanced detection, of antibodies
to antigens that are present in small amounts in cells, or are
of intrinsically low immunogenicity (Imam et al., 1990a). In
the present study, this approach was applied in an attempt to
develop antibodies with specificity for antigens present on
normal cells and absent in the corresponding malignancy.
Consequently, immune tolerance to antigens of human mam-
mary epithelial carcinoma cells (MCF.7 and MDA.MD.231
combined) was induced in neonatal mice prior to subsequent
immunisation with normal breast cells. Finally, a clone pro-
ducing a monoclonal antibody with the above property was
selected for further study. The antibody recognised an
antigen on normal MEC lines and was termed luminalA MAMMARY EPITHELIAL CELL-SURFACE GLYCOPROTEIN 443
epithelial antigen with an apparent molecular weight of
92 kDa (LEA.92).
The cells in normal breast tissue as well as benign breast
disease, such as fibroadenoma or hyperplasia, expressed
LEA.92, whereas invasive mammary carcinoma cells of both
infiltrating ductal and lobular types were negative. The
results obtained with staining of tissue sections suggest a loss
of expression of LEA.92 in invasive primary carcinoma cells
of mammary or extramammary tissues. A detailed study
using a large number of cases is warranted to map precisely
the expression of LEA.92 during the progression of
oncogenesis by incorporating tissue samples from patients
with various types of dysplasia and in situ carcinomas of
mammary and extramammary tissues.
In order to study the significance of down-regulation of
LEA.92 in the oncogenesis of breast, an in vitro model that
consists of various steps of malignant transformation of
mammary epithelial cells has been adopted. During the
preliminary study, the results using the model system indicate
a correlation between the absence of LEA.92 expression and
the development of tumorigenicity, complementing the results
obtained with tissue.
The pattern of expression of LEA.92 on MEC in culture
model systems mirrored those in tissues, as the glycoprotein
was detected on the normal or immortalised MEC lines,
which were non-tumorigenic in nude mice. In contrast,
LEA.92 was undetectable on oncogenically transformed or
established lines of mammary carcinoma cells, which were
highly tumorigenic. There are probably several possibilities
that can be attributed to the absence of reactivity of anti-
LEA.92 antibody with the malignant cells in tissues or cell
cultures. The most plausible among them, for the elimination
of the epitope recognised by the antibody, can be attributed
to a change in splicing or post-translational modifications of
LEA.92. The possible variation in the sequence can be pro-
bed by the technique of polymerase chain reaction (PCR),
once the cDNA sequence encoding LEA.92 is determined.
The effect of down-regulation of LEA.92 on the develop-
ment of tumorigenicity in vivo of mammary epithelial cell
lines is not yet known. Therefore, the biological role of
LEA.92 in the process of transformation can conceivably be
determined by incorporating experiments to determine
whether inducing expression of the glycoprotein by transfec-
tion can suppress the tumorigenic phenotype of the malig-
nant and non-expressing cells. Alternatively, it would seem at
least equally valuable to transfect non-tumorigenic cells with
antisense LEA.92 to determine whether suppression of the
glycoprotein might cause tumorigenicity. These aspects are
the subject of continuing study.
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